Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement.
暂无分享，去创建一个
P. Philip | G. Abou-Alfa | R. Kelley | A. El-Khoueiry | S. Roychowdhury | I. Borbath | M. Bitzer | W. Yong | T. Macarulla | L. Goyal | M. Javle | Ai Li | D. Waldschmidt | S. Sadeghi | S. Shepherd | S. Moran | A. Pande | Weipeng Yong | S. Tanasanvimon